NeuroPace Q1 revenue $11.4M, net loss widens to $11.5M; guides FY2022 revenue $45-48M

NeuroPace Inc

2022-Q1 EPS reported -$0.47 revenue$11,374,000

Total revenue $11.4M (+2% YoY); initial implant rev $8.8M (+9%); replacement rev $2.6M (-16%).
Net loss widened to $11.5M from $8.8M; operating expenses $18.0M vs $12.4M.
Gross margin 73% vs 76% due to higher costs and COVID disruptions; cash $103.2M.
FY2022 guidance: revenue $45-48M, initial implants $39-42M, opex $74-76M.
On track to enroll first patients in NAUTILUS trial for generalized epilepsy expansion mid-2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.